@Rhino1963 sorry my hotcopper is being weird with replies lately
If FTO inhibition decreases the expression of CDK7, what's the point of adding another potentially toxic drug into the mix?
The jury is still out on all of the possible combinations with FTO inhibitors. We have a taste of combination from the phase II pediatric trial in blood cancers using Bisantrene (FTO inhibitor) with antimetabolites (Ara-C). Efficacy was very good in a heavily pretreated, resistant population group (46% CR rate).
Cardioprotection thread, page-426
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.000(0.00%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.66 | $1.60 | $207.2K | 127.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 25510 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 12000 | 1 |
View Market Depth
| Last trade - 15.49pm 29/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |